Remote Hind Limb Ischemia Mechanism of Cardioprotection

Information

  • Research Project
  • 10438112
  • ApplicationId
    10438112
  • Core Project Number
    R01HL139047
  • Full Project Number
    3R01HL139047-04S1
  • Serial Number
    139047
  • FOA Number
    PA-20-222
  • Sub Project Id
  • Project Start Date
    7/1/2018 - 6 years ago
  • Project End Date
    6/30/2022 - 2 years ago
  • Program Officer Name
    SCHWARTZ, LISA
  • Budget Start Date
    7/1/2021 - 3 years ago
  • Budget End Date
    6/30/2022 - 2 years ago
  • Fiscal Year
    2021
  • Support Year
    04
  • Suffix
    S1
  • Award Notice Date
    8/19/2021 - 3 years ago

Remote Hind Limb Ischemia Mechanism of Cardioprotection

Although hind limb remote ischemic conditioning (RIC) is cardioprotective, the mechanism is unknown. The long-term goal of this project is to understand the mechanism of protection by remote hind-limb ischemia. The central hypothesis of this proposal is that transient ischemic episodes, away from the myocardial infarction (MI), contribute to the recovery through secretion of beneficial exosomes from skeletal muscle endocrine, improving mitochondrial metabolism, hydrogen sulfide (H2S, an anti-oxidant, anti-inflammatory, anti-apoptotic, vasoactive gas) and mobilization of bone marrow stem cells (BMSC) to the site of injury (Figure 1). It is known that DNA hypermethylation by epigenetic modification inhibits the gene and produces homocysteine (Hcy), leading to hyperhomocysteinemia (HHcy) that decreases H2S. Interestingly, increase in cystathione ? synthase (CBS) and cystathionine ? lyase (CSE) enzymes increases H2S and decreases Hcy. Our preliminary data suggests that RIC induced musclin (a skeletal muscle hormone) attenuated myocardial muscle damage and dysfunction. The central hypothesis will be tested by the following three specific aims: Specific Aim 1: To determine whether the RIC releases exosomes, induces musclin and reverses compromised skeletal and cardiac muscle function during MI and diabetes. Specific Aim 2: To determine whether the RIC enhances H2S production by increasing CBS and CSE expression, and epigenetic hypomethylation and gene induction during MI and diabetes. Specific Aim 3: To determine whether the RIC instigates BMSC mobilization to the site of myocardial injury and mitigates muscle damage by regeneration after MI during diabetes.

IC Name
NATIONAL HEART, LUNG, AND BLOOD INSTITUTE
  • Activity
    R01
  • Administering IC
    HL
  • Application Type
    3
  • Direct Cost Amount
    67007
  • Indirect Cost Amount
    37524
  • Total Cost
    104531
  • Sub Project Total Cost
  • ARRA Funded
    False
  • CFDA Code
    837
  • Ed Inst. Type
    SCHOOLS OF MEDICINE
  • Funding ICs
    NHLBI:104531\
  • Funding Mechanism
    Non-SBIR/STTR RPGs
  • Study Section
    ZRG1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    UNIVERSITY OF LOUISVILLE
  • Organization Department
    PHYSIOLOGY
  • Organization DUNS
    057588857
  • Organization City
    LOUISVILLE
  • Organization State
    KY
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    402920001
  • Organization District
    UNITED STATES